InfuSystem Receives Accreditation from the Community Health Accreditation Program (CHAP)
May 28, 2009 7:30:00 AM
Email Story Discuss on ZenoBank
View Additional ProfilesMADISON HEIGHTS, Mich., May 28 /PRNewswire-FirstCall/ -- InfuSystem (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it has received accreditation from Community Health Accreditation Program (CHAP). The accreditation is intended to ensure the highest standard of care for patients in the home health care and hospice environments. All durable medical equipment (DME) suppliers are required by the Centers for Medicare and Medicaid Services (CMS) to obtain accreditation by September 30, 2009 in order to retain their Medicare Part B DME supplier number allowing them to submit claims for reimbursement.
Mr. Steve Watkins, Chief Executive Officer, commented, "Here at InfuSystem, we have always strived to achieve the highest levels of care in the industry and we are pleased to have met the rigorous criteria required for CHAP accreditation. In addition to CMS, private insurers, hospitals, physicians, nurses, pharmacists and patients all value the CHAP accreditation. While our existing clientele are well aware of the quality of our services, this accreditation provides further third-party validation and will be beneficial for us in securing new business for our full range of services."
About InfuSystem Holdings, Inc.
InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.
SOURCE InfuSystem
----------------------------------------------
Investors
David K. Waldman or Klea K. Theoharis
Crescendo Communications
LLC
+1-212-671-1020
AI
